Benefits
Prebiotic gut-microbiome support
In the one randomized trial of Odilia (80 adults with gut dysbiosis, 300 mg a day, 8 weeks), stool sequencing after 8 weeks showed the Firmicutes to Bacteroidetes ratio fall from 2.72 to 1.56 and Bacteroides and Clostridium XIVa rise. Read that carefully: those are before-and-after numbers within the Odilia group. When the two groups were compared against each other at 4 and 8 weeks, the paper reports them as still comparable, with no significant difference in diversity or bacterial signature, and the placebo group's ratio also fell, from 2.29 to 1.69. A change in which bacteria are present is a laboratory measurement, not something you feel. Odilia also does not behave like a classic prebiotic in one respect: bifidobacteria did not increase in the Odilia group, they fell slightly.
Digestive comfort and reflux symptoms
This is the part of the trial a person would actually notice. Over 8 weeks, digestive quality-of-life scores rose 19.6% on Odilia against 11.8% on placebo, and reflux symptom scores fell 53.8% against 40.0%; both gaps were statistically significant. Individual complaints that improved more than placebo included abdominal pain, abdominal fullness, belching, abdominal noises, heartburn, early satiety and difficulty swallowing. Stool frequency and stool form were never recorded, so nothing is known about regularity. Note too that 300 mg of extract supplies very little fiber: this is not a bulking fiber dose.
Fatigue and coping with stress: two questionnaire items only
Bionap markets Odilia for a gut-brain-muscle axis. The trial measured no muscle outcome at all: no strength, no mass, no performance, nothing. What it found was that two single questions inside the digestive quality-of-life form, self-rated fatigue and ability to cope with stress, improved more on Odilia than on placebo at 8 weeks (fatigue +0.9 versus +0.3 points, coping with stress +0.9 versus +0.5). Those are two items on a gastrointestinal questionnaire, not validated fatigue or stress instruments, and the study was not designed or powered to test them. Treat this as a lead for future research, not a reason to buy.
Mechanism of action
Prebiotic fermentation
Opuntia poly- and oligosaccharides reach the colon where gut bacteria can ferment them. Laboratory work on Opuntia cladode mucilage found the large polysaccharides ferment poorly, only 11% to 27% as readily as glucose, with the smaller oligosaccharides doing better. Short-chain fatty acids have never been measured in any human study of this extract, so the SCFA step is inferred from other work, not observed.
Soluble-fiber mucilage
The cladode mucilage is a viscous soluble fiber. At 300 mg a day the amount delivered is tiny next to the gram doses used in bowel-regularity research, and no bowel-habit outcome has ever been measured with this extract. The trial authors themselves note that fiber supplements are usually dosed in grams.
Clinical trials
Randomized, double-blind, placebo-controlled, single-center parallel-group trial of Odilia 300 mg/day against a 300 mg maltodextrin placebo for 8 weeks, registered as ISRCTN14562892. Mellai M, Allesina M, Edoardo B, Cascella F, Nobile V, Spina A, et al. Nutrients 2024;16(5):586. Funded by Bionap, the company that sells Odilia; one author is a Bionap R&D employee, and the study was run at Nutratech (a Complife company). The sample size was calculated two-sided but the results were then all tested one-sided.
80 healthy adults aged 25 to 50 with gut dysbiosis of unknown cause and BMI under 30 (76 completed, 38 per arm); smokers, pregnant women, people with unstable medical disease and anyone with a condition that could interfere with the treatment were excluded, so people with diagnosed bowel disease were not studied
Primary endpoint, stool 16S sequencing: within the Odilia group the Firmicutes to Bacteroidetes ratio fell from 2.72 to 1.56 (p = 0.0012) and Bacteroides and Clostridium XIVa increased. Those are before-and-after comparisons inside one arm. Compared against each other at 4 and 8 weeks the two groups were reported as still comparable, with no significant difference in diversity or bacterial signature, and the placebo group's ratio also fell, from 2.29 to 1.69. Secondary endpoints, the symptom questionnaires, were compared between groups: GIQLI +19.6% on Odilia versus +11.8% on placebo, and GSAS reflux symptoms -53.8% versus -40.0%, both significant at 8 weeks. Bifidobacteria decreased rather than increased. Body weight, BMI, waist and hip measurements did not change. No adverse events in either arm.
Bionap's marketing refers to a human trial on gut health and wellbeing without naming it. A PubMed search for Odilia together with Opuntia returns exactly one record: the Nutrients 2024 trial above. They are the same study, published and indexed, so this is not extra evidence.
The same 80 adults as the trial above
No second trial of Odilia has been published. Everything known about this ingredient in people comes from the single 8-week study above.